Orphan drugs are an exciting potential market for investors -- due to the rarity of diseases treated by these therapies, the drugs are afforded extra patent protection, high prices for drugs. But the rules of biotech still apply -- it's important to be careful with any stock whose success is tied to a single drug. And Aegerion (NASDAQ:AEGR), with its HoFH drug Juxtapid, is a classic example. Sales haven't been impressive, and the pipeline looks pretty bare. That's not to say Juxtapid won't deliver -- It just hasn't impressed so far.

In the video below, health care analysts Michael Douglass and David Williamson give more thoughts on the stock.

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

David WilliamsonMichael Douglass, and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.